about
Prevention of poxvirus infection by tetrapyrrolesAntigenic subversion: a novel mechanism of host immune evasion by Ebola virusInhibition of influenza infection by glutathioneEffect of adjuvants on responses to skin immunization by microneedles coated with influenza subunit vaccineInfluenza virus-like particles containing M2 induce broadly cross protective immunityIntranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionVirus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in miceInduction of long-term protective immune responses by influenza H5N1 virus-like particles.Influenza vaccines based on virus-like particlesFormulation of microneedles coated with influenza virus-like particle vaccine.Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.Programming the magnitude and persistence of antibody responses with innate immunity.Influenza immunization with trehalose-stabilized virus-like particle vaccine using microneedlesNovel vaccines against influenza viruses.Emerged HA and NA mutants of the pandemic influenza H1N1 viruses with increasing epidemiological significance in Taipei and Kaohsiung, Taiwan, 2009-10.Increased immunogenicity of avian influenza DNA vaccine delivered to the skin using a microneedle patch.Cross-protection by co-immunization with influenza hemagglutinin DNA and inactivated virus vaccine using coated microneedles.Sulfonated naphthyl porphyrins as agents against HIV-1.Design of a small-molecule entry inhibitor with activity against primary measles virus strains.Transdermal influenza immunization with vaccine-coated microneedle arrays.Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skinEnhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.Host responses in human skin after conventional intradermal injection or microneedle administration of virus-like-particle influenza vaccine.Adjuvanted influenza vaccine administered intradermally elicits robust long-term immune responses that confer protection from lethal challenge.Changes in human Langerhans cells following intradermal injection of influenza virus-like particle vaccines.Immunization with a Mixture of HIV Env DNA and VLP Vaccines Augments Induction of CD8 T Cell Responses.Stability kinetics of influenza vaccine coated onto microneedles during drying and storage.Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedlesOriginal antigenic sin responses to influenza viruses.Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.Effects of stabilization of the gp41 cytoplasmic domain on fusion activity and infectivity of SIVmac239.Local response to microneedle-based influenza immunization in the skin.Protective effect of ginseng polysaccharides on influenza viral infectionIncorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles.Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligandRole of the long cytoplasmic domain of the SIV Env glycoprotein in early and late stages of infection.Delivery of DNA HIV-1 vaccine to the liver induces high and long-lasting humoral immune responsesProtection against lethal challenge by Ebola virus-like particles produced in insect cells.Pause on avian flu transmission research.
P50
Q24806638-49B79C16-FC81-4416-BE20-70E2D43B0B27Q27339643-C0A5F279-EA6F-4D4E-9BCD-1F859B50B99BQ28186020-56F32C15-5C65-4917-BC7D-07F31D3B7855Q28728791-CEFACD39-4D03-4F6D-B557-C22A0D0CF8E3Q28743472-ED2FAF8C-3F21-4218-AE06-F21ABFCD869EQ28744570-0A52AFD6-3EAE-4033-8E7F-80BD3EAFD3A7Q28748950-9822A927-BDB3-4853-83CE-FB9F62ABE700Q30375255-A0F37270-50E6-4CE0-BBEC-1F30A450FE0AQ30376236-84680836-8E47-4740-980B-7AC325FA6FAFQ30392132-624CC948-2A8D-4DD9-867D-14AD85892C71Q30393406-CD5D0BB1-DDA5-49CA-8667-29204B96E4ADQ30398435-A8018C71-9480-4578-AF38-398B473562B3Q30400144-3014F669-0BBF-46CE-B4D8-DE2DF78C4D6BQ30402208-818CA1B7-9911-4706-9DCC-45EE675F0019Q30407716-3C7C29AE-B632-4277-9E9E-A2B1F9DB4579Q30412988-191E8512-D065-4FFB-AFC2-4DE68D770F26Q30415387-25EDB3D1-37D5-4547-83AD-384DEFCF6717Q30430152-6F32A97D-65F6-4DD6-B78C-8FDA098E5CBFQ33211858-66A8B517-7458-418B-AEFD-149A3ABFED99Q33222430-0018C55D-18B6-4A6F-9875-E5776AD9C5BBQ33416417-99CBA790-61D2-4886-A21B-AE81629D4B17Q33506637-6214B691-75D4-4BA5-9BE8-76D3A72C43D9Q33557050-8F5666FE-73BB-4F25-B6A0-D007016FC13BQ33563977-56E6A892-8516-4DC3-B6CF-F3AA681A49C5Q33598298-5EC0A744-089B-47DB-96F6-78838379CFFBQ33682225-927AF2DD-CB3B-4379-A77D-F0A1C5B249CBQ33682225-EC951D95-1564-4DF8-B537-C8F84ADAE8DDQ33876108-B2725705-1616-4297-B59A-1A98DFDA8B90Q34047875-38D014F5-ACFB-4125-B29F-A84FE34CCDBCQ34307510-D817C3E0-5739-4000-B007-A170E27F1961Q34995177-851A64F7-F878-4A01-BE57-3E4086E94CE1Q35151690-FFBA5A19-48CA-4BE2-A387-AA715FB84ACBQ35508285-5DB5097A-113C-4447-8556-28DEC620C2E8Q35826992-BE21795A-C838-40C3-A430-E47B754831A3Q35839933-61BF8285-40F5-4690-B476-2F85281FD3B5Q36099235-5E993DC4-6096-429D-9184-0D46A1288E6CQ36154739-FDD46E28-BC6A-42F3-BF42-78A32E8CEA39Q36459268-0074A197-8F7D-4924-BC66-9101BEE6B704Q36571388-5CB06422-11AB-4CD9-B2C5-2C640274DD47Q37131622-581018E5-A72A-401E-B839-374C12F3B99B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Richard W. Compans
@ast
Richard W. Compans
@en
Richard W. Compans
@es
Richard W. Compans
@nl
Richard W. Compans
@sl
type
label
Richard W. Compans
@ast
Richard W. Compans
@en
Richard W. Compans
@es
Richard W. Compans
@nl
Richard W. Compans
@sl
prefLabel
Richard W. Compans
@ast
Richard W. Compans
@en
Richard W. Compans
@es
Richard W. Compans
@nl
Richard W. Compans
@sl
P1053
I-4087-2013
P106
P1153
7102263983
P21
P31
P3829
P496
0000-0003-2360-335X